[Drug interactions as exemplified by thiazolidinediones (glitazones). Commentary on the publication of Ulrich Klotz and Dietmar Sailer, "Drug interactions--their impact on safe drug therapy in the example of the new thiazolidinedione group (glitazone)"Arzneimittelforschung. 2001 Feb;51(2):112-7].
Lübben
G
G
Takeda Pharma GmbH Viktorieaallee 3-5 52066 Aachen. georg.luebben@takeda.de
Hübner
R
R
D000818:Animals; D001711:Biotransformation; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004347:Drug Interactions; D006801:Humans; D007004:Hypoglycemic Agents / Q000378:metabolism* / Q000494:pharmacology*; D007527:Isoenzymes / Q000378:metabolism; D000077205:Pioglitazone; D013844:Thiazoles / Q000378:metabolism* / Q000494:pharmacology*; D045162:Thiazolidinediones
D007004:Hypoglycemic Agents; D007527:Isoenzymes; D013844:Thiazoles; D045162:Thiazolidinediones; D003577:Cytochrome P-450 Enzyme System; D000077205:Pioglitazone